Arbor Biotechnologies IPO

Arbor Biotechnologies uses AI and machine learning to develop gene editing therapeutics that aim to treat genomic diseases. Their current pipeline focuses on liver and Central Nervous System (CNS) diseases. Arbor Biotechnologies was founded in 2016 by David Scott Ph.D., Winston Yan Ph.D., David Walt Ph.D., and Feng Zhang Ph.D. and is headquartered in Cambridge, MA.

Register for Details

For more details on financing and valuation for Arbor Biotechnologies, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Learn more about Arbor Biotechnologies

To invest in Arbor Biotechnologies pre-IPO

Can you invest in Arbor Biotechnologies pre-IPO?

Arbor Biotechnologies is a privately held company and is not publicly traded, therefore investing in Arbor Biotechnologies pre-IPO is only available to accredited investors. If you meet the accreditation criteria, you can learn more about Forge’s Secondary Marketplace and how to invest in private companies before their potential IPO. If you are not accredited, find out how to begin the process and qualify for new investment opportunities.

Can you sell shares of Arbor Biotechnologies before it goes public?

You can seek to sell your shares in Arbor Biotechnologies while it remains private. If you are considering selling, you can register today for free to get started. Once registered, a Private Market Specialist will guide you through any questions you might have. You may also continue to browse through our resources to help you understand the implications and procedures involved in selling your private market shares.

What is the pre-IPO value of my Arbor Biotechnologies shares?

To determine the value of your Arbor Biotechnologies shares, create a free account to gain access to Forge’s platform. In addition to the Forge Price, Forge Markets contains pricing information for hundreds of pre-IPO companies such as Last Closed Trade Price. A Private Market Specialist will also be available to assist you with any inquiries related to your Arbor Biotechnologies shares. You can also learn more about how to sell your private shares before getting started.

Is Arbor Biotechnologies a publicly traded company?

If you are interested in buying or selling private company shares, you can register with Forge today for free to explore your options. Registering gives you access to one of our Private Market Specialists who can guide you through the process of buying or selling. Learn more about how Forge might help you buy pre-IPO shares or sell pre-IPO shares.

To learn more about Arbor Biotechnologies potential IPO

Will Arbor Biotechnologies go IPO?

Arbor Biotechnologies has not yet filed for an IPO. However, it’s important to note that IPOs are not the sole avenue for a private company to transition to public trading. Private companies can also go public through alternative methods such as but limited to Special Purpose Acquisition Companies (SPACs), direct listings, or mergers and acquisitions. Find out which companies are eyeing an IPO on our Tech IPO Calendar 2024.

What is Arbor Biotechnologies’ IPO price?

The Arbor Biotechnologies IPO price does not exist at this time, as Arbor Biotechnologies is still a private company and has not yet conducted an IPO. To explore secondary market data and access private market pricing details and data that may be related to Arbor Biotechnologies register for Forge Markets, today.

When was Arbor Biotechnologies founded?

Arbor Biotechnologies was founded in 2016.

What is Arbor Biotechnologies funding to date?

Arbor Biotechnologies has raised $794.8MM to date.

Who are Arbor Biotechnologies’s major investors?

Surveyor Capital
Greatpoint Ventures
Section 32
Tao Capital Partners
Temasek
Undisclosed Investors
Deep Track Capital
Ono Venture Investment
Great Point Ventures
Arch Venture Partners
Piper Heartland Healthcare Capital
Arrowmark Partners
Logos Capital
Tcg Crossover Management
Tekla Capital Management
Illumina Ventures
Woodline Partners Lp
T. Rowe Price Associates
Ridgeback Capital Investments
Janus Henderson Investors
Ridgeback Capital
Vertex Pharmaceuticals
Tcg Crossover
Ally Bridge Group

Arbor Biotechnologies Funding Rounds and Valuation

Funding History Chart
Funding Round Details
Funding Date Share Class Amount Raised Price per Share Post-Money Valuation Key Investors
09/27/2024 Series C $100MM $xx.xx $262.55MM Undisclosed Investors
Price per Share
$xx.xx
Shares Outstanding
24,330,901
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
800.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Undisclosed Investors
11/09/2021 Series B $215MM $xx.xx $573.09MM Temasek, Ally Bridge Group, TCG Crossover, Arrowmark Partners, Deep Track Capital, Great Point Ventures, Illumina Ventures, Janus Henderson Investors, Logos Capital, Ono Venture Investment, Piper Heartland Healthcare Capital, Ridgeback Capital Investments, Section 32, Surveyor Capital, T. Rowe Price Associates, Tao Capital Partners, Tekla Capital Management, Woodline Partners LP, Vertex Pharmaceuticals, ARCH Venture Partners
Price per Share
$xx.xx
Shares Outstanding
12,975,254
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
800.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Temasek, Ally Bridge Group, TCG Crossover, Arrowmark Partners, Deep Track Capital, Great Point Ventures, Illumina Ventures, Janus Henderson Investors, Logos Capital, Ono Venture Investment, Piper Heartland Healthcare Capital, Ridgeback Capital Investments, Section 32, Surveyor Capital, T. Rowe Price Associates, Tao Capital Partners, Tekla Capital Management, Woodline Partners LP, Vertex Pharmaceuticals, ARCH Venture Partners
05/19/2017 Series A $16.6MM $xx.xx $27.67MM ARCH Venture Partners
Price per Share
$xx.xx
Shares Outstanding
8,887,460
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
800.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
ARCH Venture Partners
Updated on: Nov 21, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.